Standard
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial. / Düngen, Hans-dirk; Kober, Lars; Nodari, Savina; Schou, Morten; Otto, Christiane; Becka, Michael; Kanefendt, Friederike; Winkelmann, Bernhard R.; Gislason, Gunnar; Richard, Frank; Nielsen, Olav Wendelboe; Gheorghiade, Mihai; Senni, Michele.
I:
Clinical Pharmacology in Drug Development, Bind 8, Nr. 7, 2019, s. 942-951.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Düngen, H
, Kober, L, Nodari, S
, Schou, M, Otto, C, Becka, M, Kanefendt, F, Winkelmann, BR
, Gislason, G, Richard, F
, Nielsen, OW, Gheorghiade, M & Senni, M 2019, '
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial',
Clinical Pharmacology in Drug Development, bind 8, nr. 7, s. 942-951.
https://doi.org/10.1002/cpdd.633APA
Düngen, H.
, Kober, L., Nodari, S.
, Schou, M., Otto, C., Becka, M., Kanefendt, F., Winkelmann, B. R.
, Gislason, G., Richard, F.
, Nielsen, O. W., Gheorghiade, M., & Senni, M. (2019).
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial.
Clinical Pharmacology in Drug Development,
8(7), 942-951.
https://doi.org/10.1002/cpdd.633Vancouver
Düngen H
, Kober L, Nodari S
, Schou M, Otto C, Becka M o.a.
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial.
Clinical Pharmacology in Drug Development. 2019;8(7):942-951.
https://doi.org/10.1002/cpdd.633Author
Düngen, Hans-dirk ; Kober, Lars ; Nodari, Savina ; Schou, Morten ; Otto, Christiane ; Becka, Michael ; Kanefendt, Friederike ; Winkelmann, Bernhard R. ; Gislason, Gunnar ; Richard, Frank ; Nielsen, Olav Wendelboe ; Gheorghiade, Mihai ; Senni, Michele. / Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial. I: Clinical Pharmacology in Drug Development. 2019 ; Bind 8, Nr. 7. s. 942-951.
Bibtex
@article{6c50b3f03f7b43f6b328e77442e8ff88,
title = "Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial",
author = "Hans-dirk D{\"u}ngen and Lars Kober and Savina Nodari and Morten Schou and Christiane Otto and Michael Becka and Friederike Kanefendt and Winkelmann, {Bernhard R.} and Gunnar Gislason and Frank Richard and Nielsen, {Olav Wendelboe} and Mihai Gheorghiade and Michele Senni",
year = "2019",
doi = "10.1002/cpdd.633",
language = "English",
volume = "8",
pages = "942--951",
journal = "Clinical Pharmacology in Drug Development",
issn = "2160-763X",
publisher = "Wiley-Blackwell",
number = "7",
}
RIS
TY - JOUR
T1 - Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction-Results of the CHIARA MIA 1 Trial
AU - Düngen, Hans-dirk
AU - Kober, Lars
AU - Nodari, Savina
AU - Schou, Morten
AU - Otto, Christiane
AU - Becka, Michael
AU - Kanefendt, Friederike
AU - Winkelmann, Bernhard R.
AU - Gislason, Gunnar
AU - Richard, Frank
AU - Nielsen, Olav Wendelboe
AU - Gheorghiade, Mihai
AU - Senni, Michele
PY - 2019
Y1 - 2019
U2 - 10.1002/cpdd.633
DO - 10.1002/cpdd.633
M3 - Journal article
C2 - 30452784
VL - 8
SP - 942
EP - 951
JO - Clinical Pharmacology in Drug Development
JF - Clinical Pharmacology in Drug Development
SN - 2160-763X
IS - 7
ER -
